Nanologica Wins SEK 2 Million Production-Scale Order for Peptide Purification Media

Nanologica AB ( (SE:NICA) ) has provided an update.

Nanologica AB, a Swedish life science tools specialist, supplies advanced silica-based purification media to global pharmaceutical manufacturers, with a focus on peptide drugs like insulin and GLP-1 analogues. The company operates in a growing niche market supported by increasing demand for therapies targeting diabetes and obesity, and expands its offering through Syntagon’s contract manufacturing services in small molecules and peptides.

Nanologica has secured an order worth approximately SEK 2 million from an Indian peptide drug manufacturer for production-scale evaluation of its NLAB Saga purification media. The order, which will be delivered immediately, follows several years of collaboration and signals both customer confidence in product quality and broader commercial potential, including particle sizes commonly used in insulin manufacturing, potentially widening Nanologica’s addressable product mix and strengthening its position in peptide drug purification workflows.

More about Nanologica AB

Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced silica-based consumables to pharmaceutical manufacturers. Its products are designed for the purification of peptide drugs, such as insulin and GLP-1 analogues, helping increase productivity and reduce costs in a growing global niche driven by rising demand for diabetes and obesity treatments. The group also includes Syntagon, a contract manufacturer specializing in small molecules and peptides, with strengths in purification and analysis of complex pharmaceutical compounds.

Average Trading Volume: 175,338

Technical Sentiment Signal: Sell

Current Market Cap: SEK128.2M

For a thorough assessment of NICA stock, go to TipRanks’ Stock Analysis page.